Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol
- Correspondence to: Dr. Julian Kenyon, The Old Brewery, High Street, Twyford, Winchester Hants SO21 1RG, UK. Tel: +44 01962 718000, Fax: +44 01962 717060, e-mail: firstname.lastname@example.org
Background/Aim: Cannabinoids are widely used in the management of pain, nausea and cachexia in cancer patients. However, there has been no objective clinical evidence of any anticancer activity yet. The aim of this study was to assess the effects of pharmaceutical-grade synthetic cannabidiol on a range of cancer patients. Patients and Methods: We analysed the data routinely collected, as part of our treatment program, in 119 cancer patients over a four-year period. Results: Clinical responses were seen in 92% of the 119 cases with solid tumours including a reduction in circulating tumour cells in many cases and in other cases, a reduction in tumour size, as shown by repeat scans. No side-effects of any kind were observed when using pharmaceutical grade synthetic cannabidiol. Conclusion: Pharmaceutical-grade synthetic cannabidiol is a candidate for treating breast cancer and glioma patients.
The phytocannabinoids are a group of chemicals extracted from the cannabis plant. A number of them are able to impede cancer cell growth, induce apoptosis and autophagy, and inhibit angiogenesis. The most widely known phytocannabinoid is Δ9-tetrahydrocannabinol (THC), and although it possesses these anticancer effects, it is also psychoactive, which has arguably hampered its clinical development. It is thought that these actions are mediated, in part, by binding to cannabinoid receptors that are expressed on a number of tissue types (1). As one type of the receptor is found exclusively on brain cells, studies using THC have focused on this tissue type. In vitro data were promising and, in 2016, a pilot clinical study in patients with glioblastoma multiforme indicated THC was safe; however, no clear activity was reported (2). The dosages were possibly on the conservative side, to minimise psychoactivity that would naturally restrict the use of THC as drug.
Of the 80+ phytocannabinoids, THC is possibly the only one to exhibit this psychoactivity. More recently, studies have diverted away from THC and focussed on other cannabinoids. The next most abundant compound is cannabidiol (CBD), which has a low affinity for the canonical cannabinoid receptors. In contrast to THC, in its pure state, according to the World Health Organisation, CBD did not have abuse potential and caused no harm (3). Studies have shown that in addition to being able to induce cell death directly, it is also capable of interfering with intracellular signalling (4). Alterations to pathways such as the PI3K/AKT/mTOR and the ERK, suggests that CBD can modify the way certain cancer cells react to other treatments. Indeed, studies have shown that combining CBD with conventional chemotherapy such as cytarabine and vincristine can lead to enhanced anticancer activity through modifications to these signalling pathways (5, 6). Furthermore, the sequence in which these drugs are administered can also influence overall activity (5). Studies have also indicated that in certain leukaemia cell lines, CBD can increase the expression of the cyclin-dependent kinase inhibitor p21waf1 (6). This increased level appears to be maintained by CBD, which inadvertently impedes cell death. Cytotoxicity can be restored in these cells if the treatment regimen was altered to allow for a temporary cessation of exposure to CBD. Thus, the general efficacy of CBD may also be altered by adapting treatment protocols that include “drug-free” phases (6).
The findings of a number of studies designed to examine the role of cannabinoids in in the management of cancer symptoms varied (7). The most recent prospective analysis of nearly 3,000 patients using medical marijuana showed that a large proportion of patients reported improvement in their condition (8). Patients often feel that conventional therapies are not working for them, and so they search the internet for alternative medicines. It is here that they find stories about cannabis working in patients with cancer, and understandably feel it is a route for them. The cannabis products they use vary, and can be in the form of whole-plant extracts or purified oils; however, whatever the source, they self-prescribe dosages. A number of anecdotal positive responses have been reported, which sustains the interest in this type of medication.
In order to assess its potential use, we focused on giving patients with advanced cancer who requested CBD a pharmaceutical-grade synthetic product at appropriate doses. Activity of synthetic cannabinoid WIN on human cancer cell lines has been reported (9). Every patient in this study signed an informed consent allowing anonymous use of their data.
Patients were given synthetic, pharmaceutical-grade CBD (STI Pharmaceuticals), registered under the Pharmaceutical Specials scheme in oily drops at 5% (w/v) in 20 ml bottles. Each drop contained 1 mg of synthetic CBD in neutral oil. This was prescribed on an informed consent basis. 119 cancer patients decided to have this treatment (Table I), and most of them had metastatic cancers. Of the 119 patients, 28 were given CBD as the only treatment. A third of these patients had already been taking cannabis oil extracted from the cannabis plant that had been bought on the Internet, with no beneficial response. This is currently illegal, as the Medicines and Health Regulatory Agency has defined CBD as a medicinal product, which can only be prescribed under the Pharmaceutical Specials scheme, as it is not currently a licensed medicinal product (10).
The majority of the patients were assessed using a circulating tumour cell test before and after treatment (11), since this is cheaper than carrying out repeated scans. A number of patients however, as a matter of a normal treatment course, had relevant scans. CBD was administered on three days on and three days off basis, which clinically was found to be more effective than giving it as a continuous dose. The average dose was 10 mg twice a day. For increased tumour mass, the dose was increased, in some cases up to 30 drops twice a day (30 mg). In a number of cases where stable disease was present, the dose was reduced to five drops twice a day (5 mg). In some cases, Sativex, which is licensed for use in multiple sclerosis, was used in conjunction with CBD as a source of THC, which synergises with CBD (12). A fraction of the dose used for multiple sclerosis was used. Two sprays of Sativex were given twice a day in three days on and three days off pattern, as in the case of pharmaceutical-grade synthetic CBD; patients on continuous dosing did not do as well as those on this on-off repeating regimen. Some of our patients reverted to cannabis oil bought on the Internet, and following this, 80% of these cases relapsed.
We were unable to define a maximum tolerated dose for CBD, as there was a complete absence of side effects. The minimum duration of treatment required for CBD was six months, but many continued for longer. Less than six months appeared inadequate and had little effect, and therefore cases in which CBD was used for less than six months have been defined as un-assessable, and not included in the current cohort of 119 cases.
We sought clear objective evidence of potential efficacy where no other treatment option was available. The most impressive case was a five-year-old male patient with an anaplastic ependymoma, a very rare brain tumour. The patient had had all standard treatments, surgery on two occasions followed by chemotherapy and conformal photon radiotherapy. No further treatment options were available to him when treatment on CBD started in February 2016. A scan carried out in December 2016 showed that tumour volume had decreased by ~60%. Further scans, carried out since December 2016, continued to show stable disease. CBD was the only treatment. Four scans with the scan report at the top of each scan are appended (Figure 1A-D).
Another impressive case was a 50-year-old patient with progressive tanycytic ependymoma Grade 2 diagnosed in June 2013, treated with biopsy and radical radiotherapy, which was completed on 3rd June 2015. He refused chemotherapy, and had no further treatment options. He started on pharmaceutical-grade synthetic CBD in July 2016 at a dose of 10 drops twice a day, three days on and three days off (10 mg). Prior to this he had been taking, for some time, metformin, mebendazole, doxycycline and atorvastatin from an oncology clinic in Central London.
In January 2017 a repeat scan showed tumour reduction. At that point the patient stopped taking pharmaceutical-grade synthetic CBD and switched to cannabis oil extract obtained from an internet website. Further scans carried out in February 2018 showed doubling of tumour size and more growth down the brain stem. He has since restarted pharmaceutical-grade synthetic CBD and throughout continued to take the metformin, atorvastatin, doxycycline and mebendazole. So, the only change in November 2017 had been stopping the pharmaceutical-grade synthetic CBD and switching to cannabis oil extract obtained on the Internet (Figure 2A and B).
Other patients who clearly improved using pharmaceutical-grade synthetic CBD had prostate cancer, breast cancer, oesophageal cancer and a lymphoma, and these are summarised in Table II
From our laboratory studies, we would not expect any significant anti-cancer activity using continuous CBD alone, as we have only observed cancer cell line apoptosis (cell death) when the agent is washed out of culture and withdrawn (13). We have also observed a potential increased cell killing ability when given after chemotherapy.
Cannabinoids have an accepted useful role in the management of cancer symptoms, namely pain control, nausea and cachexia, but not as part of primary treatment. The fact that we have been able to document improvement in cancer in few patients strongly supports further studies of CBD-based products in cancer patients who have exhausted standard treatments. Our primary data in a murine glioma model (14) showing enhanced sensitivity to radiotherapy without any side-effects, suggests this would be an ideal clinical trial to initiate in the first instance.
This article is freely accessible online.
Conflicts of Interest
There are no conflicts of interest to disclose.
- Received August 22, 2018.
- Revision received September 12, 2018.
- Accepted September 21, 2018.
- Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved